Cannabis & Wellness

As the old AYR Wellness liquidates, its key assets are reborn under creditor control. A forensic look at the deal, the debt, and what it signals for the industry.

A breakthrough in cardiac fibrosis treatment reveals more than a new drug; it signals a systemic shift. How AI and human 'organoids' are making animal models obsolete.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

ITG Brands acquires innovator Black Buffalo for $150M, diversifying beyond nicotine pouches to capture a new segment of smokeless alternative users.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

A new report reveals Europe's medically-focused cannabis market is finally waking, creating a new global blueprint but also intense competition and price wars.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

Cannabis giant Curaleaf is rolling the dice with a reverse stock split, aiming for a coveted spot on a major U.S. exchange ahead of federal rescheduling.

MedX Holdings rebrands to Dazed Inc., launching a multi-city expansion and new coffee line to capitalize on cannabis's landmark move to Schedule III.

At SLAS 2026, MGI Tech unveiled intelligent platforms for proteomics and clinical automation, signaling a major push to accelerate scientific discovery.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

New FolinicActive™ offers a multi-pathway folate for the 15-25% of adults who report adverse effects from standard L-methylfolate supplements.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

Beyond fat removal, a new wave of cosmetic surgery in Dubai uses advanced tech to craft athletic, natural bodies, making the city a global beauty hub.

Amid tourism recovery and new delivery laws, NUGL reports strong Q1 earnings, signaling a new era for Jamaica's burgeoning regulated cannabis industry.

Natrol launches Ultra Sleep and Energy, partnering with Calm and Michelle Monaghan in a bold move to connect restorative rest with daytime vitality.

BioAdaptives completes its MyndSystem™ with a new nighttime nootropic, aiming to capture the overlooked market for overnight brain recovery.